Nimmagadda SC, Frey S, Edelmann B, Hellmich C, Zaitseva L, König GM, Kostenis E, Bowles KM and Fischer T. Bruton's Tyrosine Kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.
Leukemia 2017; doi: 10.1038/leu.2017.324. [Epub ahead of print]

Ranjan S, Goihl A, Kohli S, Gadi I, Pierau M, Shahzad K, Gupta D, Bock F, Wang H, Shaikh, H, Kähne T, Reinhold D, Bank U, Zenclussen AC, Niemz J, Schnöder TM, Brunner-Weinzierl M, Fischer T, Kalinski T, Schraven B, Luft T, Huehn J, Naumann M, Heidel FH, Isermann B. Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.
Nat Commun 2017; 8(1):311

Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T*, Heidel F*. Cell autonomous expression of CXCL-10 in JAK2-V617F mutated CMN.
J Cancer Res Clin Oncol 2017; 143 (5):807-820; *shared corresponding authorship.

Gupta N, Edelmann B, Schnoeder TM, Saalfeld FC, Wolleschak D, Kliche S, Schraven B, Heidel FH*, Fischer T*. JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1 (VCAM1).
Leukemia 2017; 31 (5):1223-1226. *shared corresponding authorship.

Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D. Gain of function in JAK2-V617F-positive T-cells.
Leukemia 2017; 31(4):1000-1003.

Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, Heidel FH. Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.
Leukemia 2016; 30:991-995.

Ebert C, Perner F, Wolleschak D, Schnöder TM, Fischer T, Heidel FH. (2016) Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.
Haematologica 2016; 101: e81-5.

Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T*, Heidel FH*. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.
Leukemia 2016; 30:1220-1225. *shared corresponding authorship.

Bongartz H, Hessenkemper W, Müller C, Fensky M, Fritsch J, Mandel K, Behrmann, I, Haan C, Fischer T, Feller SM, Schaper F.
The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
Cell Signal 2017 ;35:37-47.

Arra A, Lingel H, Kuropka B, Pick J, Schnoeder T, Fischer T, Freund C, Pierau M, Brunner-Weinzierl MC. The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs.
Oncoimmunology 2017 ;6(2):e1273300.

Einsele H, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Straka C. Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.
Leukemia 2017; 31(6):1463-1466.

Schalk E, Zeremski V, Fischer T. Impact of lymphopenia on prognosis of patients with primary central nervous system lymphoma.
Eur J Cancer 2017;75:280-283.

Schlenk RF, Frech P, Weber D, Brossart P, Horst HA, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih HR, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik VI, Teleanu V, Heuser M, Thol F, Döhner K,Krauter J, Ganser A, Döhner H; and for the German-Austrian AMLSG. Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.
Leukemia 2017; 31(5):1217-1220.

Gieseler-Halbach S, Meltendorf S, Pierau M, Weinert S, Heidel FH, Fischer T, Handschuh J, Braun-Dullaeus RC, Schrappe M, Lindquist JA, Mertens PR, Thomas U, Brunner-Weinzierl MC. RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts.
Cell Death Differ 2017; 24(2):371-383.

Perner F, Schnöder TM, Fischer T, Heidel FH. Kinomics Screening Identifies Aberrant Phosphorylation of CDC25C in FLT3-ITD-positive AML.
Anticancer Res 2016, 36(12):6249-6258.

Schalk E, Fischer T. Hemophagocytic lymphohistiocytosis as an unusual cause of prolonged bicytopenia after chemotherapy.
Clin Case Rep 2016; 4(10):1017-1018.

Schalk E, Fischer T. Biased Low Incidence of Central Venous Catheter-Related Bloodstream Infections in Controlled Clinical Trials?
Infect Control Hosp Epidemiol 2016; 37(5):617-9.

Zeremski V, Koehler M, Fischer T, Schalk E. Characteristics and outcome of patients with primary CNS lymphoma in a "real-life" setting compared to a clinical trial.
Ann Hematol 2016; 95(5):793-9.

Sasse S, Alram M, Müller H, Smardová L, Metzner B, Doehner H, Fischer T, Niederwieser DW, Schmitz N, Schäfer-Eckart K, Raemaekers JM, Schmalz O, Tresckow BV, Engert A, Borchmann P. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.
Leuk Lymphoma 2016; 57(5):1067-73.

Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T, Heidel FH. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.
Leukemia 2016; 30(5):1220-5.

Kahl C, Krahl R, Becker C, Al-Ali HK, Sayer HG, Schulze A, Herold M, Hänel M, Scholl S, Hochhaus A, Uharek L, Maschmeyer G, Haehling D, Junghanß C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf HH, Niederwieser D. Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).
J Cancer Res Clin Oncol 2016; 142(1):305-15.

Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schröder K, Shah AM, Fischer M, Scholl S, Barth J, Oellerich T, Berg T, Serve H, Frey S, Fischer T, Heidel FH, Böhmer FD. NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.
Leukemia 2016; 30(2):473-83.

Lipka DB, Wagner MC, Dziadosz M, Fischer T. Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.
Leukemia 2016, 30(10):2090-2093.

Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Lancet. 2016; 388(10044):565-75.

Leukemogenic potency of the novel FLT3-N676K mutant. Huang K, Yang M, Pan Z, Heidel F, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z
Annals of Hematology 2016, 95(5):783-91.

Ebert C, Perner F, Wolleschak D, Schnöder TM, Fischer T, Heidel FH. Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.
Haematologica. 2015 101(3):e81-5

Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T, Heidel FH. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo
Leukemia 2016 May;30(5):1220-1225.

Kahl C, Krahl R, Becker C, Al-Ali HK, Sayer HG, Schulze A, Herold M, Hänel M, Scholl S, Hochhaus A, Uharek L, Maschmeyer G, Haehling D, Junghanß C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf HH, Niederwieser D. Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).
J Cancer Res Clin Oncol 2016 Jan;142(1):305-15.

Schalk E, Hanus L, Färber J, Fischer T, Heidel FH. Prediction of central venous catheter-related bloodstream infections (CRBSIs) in patients with haematologic malignancies using a modified Infection Probability Score (mIPS).
Ann Hematol 2015; 94(9):1451-6.

Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schröder K, Shah AM, Fischer M, Scholl S, Barth J, Oellerich T, Berg T, Serve H, Frey S, Fischer T, Heidel FH, Böhmer FD. NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.
Leukemia 2016 ;30(2):473-83.

Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, Heidel FH. Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function
Leukemia 2016, 30(4):991-5.

Schalk E, Färber J, Fischer T, Heidel FH. Central Venous Catheter-Related Bloodstream Infections in Obese Hematologic Patients.
Infect Control Hosp Epidemiol 2015; 36(8):995-6.

Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Neurology 2015; 84(12):1242-8.

Koehler M, Fischer T. How health-related quality-of-life outcomes in patients with acute promyelocytic leukemia can help physicians in decision making.
J Clin Oncol 2015; 33(9):1090-1.

Heidel FH, Arreba-Tutusaus P, Armstrong SA, Fischer T. Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia's genetic diversity.
Clin Cancer Res 2015; 21(2):240-8.

Schnöder TM, Arreba-Tutusaus P, Griehl I, Bullinger L, Buschbeck M, Lane SW, Döhner K, Plass C, Lipka DB, Heidel FH, Fischer T. Epo-induced erythroid maturation is dependent on Plcγ1 signaling.
Cell Death Differ 2015; 22(6):974-85.

Neumann J, Riek-Burchardt M, Herz J, Doeppner TR, König R, Hütten H, Etemire E, Männ L, Klingberg A, Fischer T, Görtler MW, Heinze HJ, Reichardt P, Schraven B, Hermann DM, Reymann KG, Gunzer M. Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke
Acta Neuropathol 2015; 129(2):259-77.

Benderska N, Ivanovska J, Rau TT, Schulze-Luehrmann J, Mohan S, Chakilam S, Gandesiri M, Ziesché E, Fischer T, Söder S, Agaimy A, Distel L, Sticht H, Mahadevan V, Schneider-Stock R. DAPK-HSF1 interaction as a new positive feedback loop for TNF-induced apoptosis in colorectal cancer cells
J Cell Sci 2014; 127(Pt 24):5273-87.

Heinicke T, Hütten H, Kalinski T, Franke I, Bonnekoh B, Fischer T. Sustained remission of blastic plasmacytoid dendritic cell neoplasm after unrelated allogeneic stem cell transplantation-a single center experience
Ann Hematol 2015; 94(2):283-7.

Krüger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, Grobe N, Maschmeyer G, Niederwieser D, Dölken G. Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO).
Ann Hematol 2014; 93(9):1587-97.

Schalk E, Färber J, Fischer T. Multidrug-Resistant Gram-Negative Bacteria in Hematology and Oncology
Infect Control Hosp Epidemiol. 2014 Sep;35(9):1203-1204.

Koehler M, Fischer T, Kropf S, Frommer J. Quantitative tool to evaluate the somatic burden due to chemotherapy-induced adverse events: the somatic burden score
Support Care Cancer 2014; 22(11):3089-99.

Wolleschak D, Mack TS, Perner F, Frey S, Schnöder TM, Wagner MC, Höding C, Pils MC, Parkner A, Kliche S, Schraven B, Hebel K, Brunner-Weinzierl M, Ranjan S, Isermann B, Lipka DB, Fischer T, Heidel FH. Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
Haematologica 2014; 99(6):e90-3.

van Roeyen CR, Scurt FG, Brandt S, Kuhl VA, Martinkus S, Djudjaj S, Raffetseder U, Royer HD, Stefanidis I, Dunn SE, Dooley S, Weng H, Fischer T, Lindquist JA, Mertens PR. Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities
Cell Commun Signal 2013; 11:63.

Schalk E, Geginat G, Schulz C, Schlüter D, Fischer T. The incidence of norovirus infections in cancer patients shows less seasonal variability compared to patients with other diseases.
Ann Hematol 2014; 93(5):889-90.

Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE. Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial.
J Clin Oncol 2013; 31(25):3110-8.

Heidel FH , Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Dohner K, Vasioukhin V, Fischer T, Armstrong S. The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML.
J Exp Med 2013; 210(1):15-22.

Wagner MC, Dziadosz M, Melo JV, Heidel FH, Fischer T, Lipka DB. Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells.
Leukemia. 2013; 27(7):1567-70.

Deangelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
Leukemia 2013; 27(8):1628-36.

Caldarelli A, Müller JP, Paskowski-Rogacz M, Herrmann K, Bauer R, Koch S, Henninger AK, Krastev D, Ding L, Kasper S, Fischer T, Brodhun M, Böhmer FD, Buchholz F. A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling.
Leukemia 2013; 27(12):2301-10.

Van Roeyen CR, Scurt FG, Brandt S, Kuhl VA, Martinkus S, Djudjaj S, Raffetseder U, Royer HD, Stefanidis I, Dunn SE, Dooley S, Weng H, Fischer T, Lindquist JA, Mertens PR. Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities.
Cell Commun Signal 2013; 11(1):63.

Wolleschak D, Schalk E, Krogel C, Schnoeder TM, Luehr H, Jentsch-Ullrich K, Fischer T, Heidel FH. Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.
J Hematol Oncol 2013; 6(1):39.

Ivanovska J, Tregubova A, Mahadevan V, Chakilam S, Gandesiri M, Benderska N, Ettle B, Hartmann A, Söder S, Ziesché E, Fischer T, Lautscham L, Fabry B, Segerer G, Gohla A, Schneider-Stock R. Identification of DAPK as a scaffold protein for the LIMK/cofilin complex in TNF-induced apoptosis.
Int J Biochem Cell Biol 2013; 45(8):1720.

Schalk E, Geginat G, Schulz, C, Schlüter D, Fischer T. The incidence of norovirus infections in cancer patients shows less seasonal variability compared to patients with other diseases.
Ann Hematol 2014; 93(5):889-90.